CRESCENT BIOPHARMA, INC. Stock or Unit Option Plan Expense
CRESCENT BIOPHARMA, INC. (CBIO) reported Stock or Unit Option Plan Expense of $2.24 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-04.
Discontinued › Cash Flow
us-gaap:StockOptionPlanExpense · last filed 2016-11-04
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for the quarter ending 2016-09-30 was $739.41K, a 16.83% increase year-over-year.
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for the quarter ending 2016-06-30 was $771.69K, a 68.41% increase year-over-year.
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for the quarter ending 2016-03-31 was $727.55K, a 23.83% increase year-over-year.
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for the quarter ending 2015-12-31 was $644.93K, a 33.63% increase year-over-year.
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for fiscal 2015 was $2.32M, a 42.11% increase from fiscal 2014.
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for fiscal 2014 was $1.64M, a 284.10% increase from fiscal 2013.
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for fiscal 2013 was $425.69K, a 2.52% increase from fiscal 2012.
- CRESCENT BIOPHARMA, INC. stock or unit option plan expense for fiscal 2012 was $415.21K.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month | Stock or Unit Option Plan Expense 130 month |
|---|---|---|---|---|---|
| 2016-09-30 | $739.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.51M derived: sum of 2 quarters · filed 2016-11-04 | $2.24M 10-Q · filed 2016-11-04 | $2.88M derived: sum of 4 quarters · filed 2016-11-04 | |
| 2016-06-30 | $771.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.50M 10-Q · filed 2016-08-04 | $2.14M derived: sum of 3 quarters · filed 2016-08-04 | $2.78M derived: sum of 4 quarters · filed 2016-11-04 | |
| 2016-03-31 | $727.55K 10-Q · filed 2016-05-04 | $1.37M derived: sum of 2 quarters · filed 2016-05-04 | $2.01M derived: sum of 3 quarters · filed 2016-11-04 | $2.46M derived: sum of 4 quarters · filed 2016-11-04 | |
| 2015-12-31 | $644.93K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $1.28M derived: sum of 2 quarters · filed 2016-11-04 | $1.74M derived: sum of 3 quarters · filed 2016-11-04 | $2.32M 10-K · filed 2016-02-29 | |
| 2015-09-30 | $632.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.09M derived: sum of 2 quarters · filed 2016-11-04 | $1.68M 10-Q · filed 2016-11-04 | $2.16M derived: sum of 4 quarters · filed 2016-11-04 | |
| 2015-06-30 | $458.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.05M 10-Q · filed 2016-08-04 | $1.53M derived: sum of 3 quarters · filed 2016-08-04 | $1.97M derived: sum of 4 quarters · filed 2016-08-04 | |
| 2015-03-31 | $587.51K 10-Q · filed 2016-05-04 | $1.07M derived: sum of 2 quarters · filed 2016-05-04 | $1.51M derived: sum of 3 quarters · filed 2016-05-04 | $1.93M derived: sum of 4 quarters · filed 2016-05-04 | |
| 2014-12-31 | $482.64K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $924.42K derived: sum of 2 quarters · filed 2016-02-29 | $1.34M derived: sum of 3 quarters · filed 2016-02-29 | $1.64M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $441.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $860.20K derived: sum of 2 quarters · filed 2015-11-12 | $1.15M 10-Q · filed 2015-11-12 | $1.21M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $418.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $710.64K 10-Q · filed 2015-08-06 | $771.25K derived: sum of 3 quarters · filed 2016-02-29 | $918.66K derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $292.22K 10-Q · filed 2015-05-05 | $352.82K derived: sum of 2 quarters · filed 2016-02-29 | $500.23K derived: sum of 3 quarters · filed 2016-02-29 | $609.89K derived: sum of 4 quarters · filed 2016-02-29 | $1.71M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $60.61K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $208.01K derived: sum of 2 quarters · filed 2016-02-29 | $317.68K derived: sum of 3 quarters · filed 2016-02-29 | $425.69K 10-K · filed 2016-02-29 | |
| 2013-09-30 | $147.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | $257.07K derived: sum of 2 quarters · filed 2014-10-31 | $365.08K 10-Q · filed 2014-10-31 | ||
| 2013-06-30 | $109.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $217.67K 10-Q · filed 2014-07-31 | |||
| 2013-03-31 | $108.01K 10-Q · filed 2014-05-09 | ||||
| 2012-12-31 | $415.21K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |